We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis

This study has been withdrawn prior to enrollment.
(Souces of funding have been terminated)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01479231
First Posted: November 24, 2011
Last Update Posted: April 19, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jeffrey A Alexander, Mayo Clinic
  Purpose
The investigators will determine the prevalence of gastroesophageal reflux disease (GERD) in Eosinophilic Esophagitis (EoE) and importantly determine the predictors of response to Proton Pump Inhibitor (PPI) therapy in EoE. Moreover, the investigators will determine the effect of GERD on the location of esophageal eosinophilia.

Condition Intervention Phase
Gastroesophageal Reflux Disease Eosinophilic Esophagitis Dysphagia Drug: dexlansoprazole Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Predictors of PPI Response in Eosinophilic Esophagitis

Resource links provided by NLM:


Further study details as provided by Jeffrey A Alexander, Mayo Clinic:

Primary Outcome Measures:
  • Prevalence of Gastroesophageal Reflux Disease [ Time Frame: 24 hour ]
    Prevalence of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis (EoE) Description: The definition of GERD is acid exposure time of >4.2% over 24 hour period, as measured by pH monitoring.


Secondary Outcome Measures:
  • Heartburn/regurgitation [ Time Frame: 30 day ]
    Heartburn/regurgitation (as measured by:) Mayo Dysphagia Questionnaire - 30 Day Validated 28 item instrument; 0 = no dysphagia, higher levels indicate greater dysphagia severity. Dysphagia. 2010 Sep;25(3):221-30 Measured by "units on a scale"

  • Abnormal 24 hour acid exposure [ Time Frame: 24 hour ]
    Abnormal 24 hour acid exposure (as measured by pH monitoring) Description: A thin plastic catheter is passed through one nostril, down the back of the throat, and into the esophagus as the patient swallows. The tip of the catheter contains a sensor that senses acid. The catheter protruding from the nose is connected to a recorder that registers each reflux of acid. The catheter is in place for 24 hours, when is removed and the recorder is attached to a computer so that the data can be downloaded.

  • Ratio of distal/proximal mean esophageal eosinophil number [ Time Frame: 6 weeks ]
    Ratio of distal/proximal mean esophageal eosinophil number (as measured by biopsies taken during esophagogastroduodenoscopy (EGD))

  • Mean distal eosinophil number [ Time Frame: 6 weeks ]
    Mean distal eosinophil number (as measured by biopsies taken during esophagogastroduodenoscopy (EGD) )


Enrollment: 0
Study Start Date: March 2012
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: dexlansoprazole Drug: dexlansoprazole
Dexlansoprazole 60 mg daily for 6 weeks
Other Name: Dexilant

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age < 80 years of age
  • 14 eosinophils / hpf on biopsies from esophagus

    • Abnormal validated Mayo dysphagia questionnaire (MDQ-30) (question 2"yes", question 4 > "moderate" and question 7 > "once a week")
    • Clinically performed EGD with > 14 eosinophils/hpf completed within last 3 months

Exclusion Criteria:

  • Other cause of dysphagia identified at endoscopy (e.g. stricture, web, infection, ring, achalasia, esophageal neoplasm)
  • Dilatation of esophagus at time of index endoscopy
  • Treatment with topical steroid within 3 months of index endoscopy
  • Treatment with PPI in last 30 days prior to index EGD

Patient population - adults with EoE recruited from Mayo Clinic Rochester, MN patient population

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01479231


Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Jeffrey A Alexander, MD Mayo Clinic
  More Information

Responsible Party: Jeffrey A Alexander, MD, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01479231     History of Changes
Other Study ID Numbers: 11-003759
First Submitted: November 22, 2011
First Posted: November 24, 2011
Last Update Posted: April 19, 2012
Last Verified: April 2012

Keywords provided by Jeffrey A Alexander, Mayo Clinic:
GERD
Eosinophilic esophagitis
Proton pump inhibitor
dysphagia

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophagitis
Deglutition Disorders
Eosinophilic Esophagitis
Esophageal Motility Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Pharyngeal Diseases
Otorhinolaryngologic Diseases
Eosinophilia
Leukocyte Disorders
Hematologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Proton Pump Inhibitors
Dexlansoprazole
Lansoprazole
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Ulcer Agents
Gastrointestinal Agents